Ornithine phenylacetate: Phase IIb amended

Ocera will increase enrollment to about 230 patients from 140 in the double-blind, placebo-controlled, U.S. Phase IIb STOP-HE trial evaluating 10, 15 and 20 g IV OCR-002 daily plus standard of care (S...